Several analysts have recently updated their ratings and price targets for Loxo Oncology (NASDAQ: LOXO):

  • 8/29/2017 – Loxo Oncology was downgraded by analysts at JMP Securities from an “outperform” rating to a “market perform” rating. They now have a $17.14 price target on the stock, down previously from $83.12. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 8/12/2017 – Loxo Oncology was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Loxo Oncology, Inc. is a biopharmaceutical company. It develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Loxo Oncology, Inc. is headquartered in Stamford, Connecticut. “
  • 8/12/2017 – Loxo Oncology was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 8/10/2017 – Loxo Oncology had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $94.00 price target on the stock, up previously from $71.00.
  • 8/9/2017 – Loxo Oncology was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $82.00 price target on the stock. According to Zacks, “Loxo Oncology, Inc. is a biopharmaceutical company. It develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Loxo Oncology, Inc. is headquartered in Stamford, Connecticut. “
  • 8/8/2017 – Loxo Oncology had its “outperform” rating reaffirmed by analysts at Ifs Securities.
  • 8/4/2017 – Loxo Oncology was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 8/3/2017 – Loxo Oncology had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $75.00 price target on the stock. They wrote, “Today LOXO announced the acquisition of REDX08608 (LOXO-305) from Redx Pharma (REDX, Not Rated), a reversible BTK inhibitor that is effective against both wild-type and mutant C481S BTK. We view the acquisition of REDX08608 positively, as the ~$40m upfront acquisition cost is relatively devoid of downstream payments (milestones etc.), and despite the BTK space being competitive with next generation programs to ibrutinib, we think there will be ample room for multiple BTK inhibitors and we also favor the selectivity of LOXO-305. Management has guided for the submission of an IND during 2018. We reiterate our Buy rating and $75 PT.””
  • 8/3/2017 – Loxo Oncology had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $71.00 price target on the stock.
  • 7/16/2017 – Loxo Oncology was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.

Loxo Oncology, Inc. (NASDAQ LOXO) traded up 1.88% during mid-day trading on Wednesday, hitting $79.22. 259,553 shares of the stock were exchanged. Loxo Oncology, Inc. has a 52 week low of $17.14 and a 52 week high of $83.12. The stock’s market cap is $2.36 billion. The company has a 50 day moving average price of $73.71 and a 200 day moving average price of $57.32.

Loxo Oncology (NASDAQ:LOXO) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.99) by $0.15. During the same quarter in the previous year, the business earned ($0.77) earnings per share. Analysts expect that Loxo Oncology, Inc. will post ($4.54) EPS for the current fiscal year.

In other news, Director Keith T. Flaherty sold 7,250 shares of the business’s stock in a transaction on Monday, August 21st. The stock was sold at an average price of $72.26, for a total transaction of $523,885.00. Following the completion of the transaction, the director now owns 20,432 shares of the company’s stock, valued at approximately $1,476,416.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Lori Anne Kunkel sold 10,000 shares of the business’s stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $75.17, for a total value of $751,700.00. Following the transaction, the director now directly owns 16,840 shares of the company’s stock, valued at approximately $1,265,862.80. The disclosure for this sale can be found here. Insiders have sold a total of 46,073 shares of company stock valued at $3,397,662 in the last three months. 27.80% of the stock is owned by insiders.

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Receive News & Ratings for Loxo Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.